Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

ested to study Abbott's Bcl-2 family protein inhibitors, which is an indication of the potential value that ABT-263 might bring to the cancer research field," said John Leonard, M.D., senior vice president, Pharmaceuticals, Research and Development, Abbott. "We have built an early stage pipeline that targets the processes that cancers need to survive and we're looking forward to advancing our work in this area."

Presentation highlights include:

-- A Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy

of ABT-263 in Subjects With Refractory or Relapsed Lymphoid

Malignancies

-- Reduction in Platelet Counts as a Mechanistic Biomarker and Guide for

Adaptive Dose-escalation in Phase I Studies of the Bcl-2 Family

Inhibitor ABT-263

-- Dynamic Contrast Enhanced MRI (DCE MRI) for Assessment of Effects of

Anti-Angiogenic Therapy: Comparison of the Transfer Constant (Ktrans)

to Blood Flow and Permeability Derived by a Distributed Parameter

Model

-- Relationship of Dose of ABT-869 on Biomarkers of Angiogenesis and

Their Correlation With Pharmacodynamic (PD) Outcome

Study Background and Results

ABT-263

Thirty patients with refractory or relapsed lymphoid malignancies have been enrolled in an ongoing Phase I study evaluating safety, pharmacokinetics and efficacy. Subjects received ABT-263 orally once daily for 14 consecutive days followed by seven days off drug in each cycle of therapy. Results showed that ABT-263 had an acceptable side-effect profile at the seven-dose (10, 20, 40, 80, 160, 225 and 315 mg) cohort levels and showed evidence of anti-tumor activity. Researchers observed 99 percent and 36 percent tumor reduction in two patients with bulky chronic lymphocytic leukemia (CLL). Another patient with bulky CLL/small lymphocytic lymphoma (SLL) experienced a 75 percent reduction and a patient with follicular lymphom
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Burien Nursing and Rehabilitation ... Care, Inc. with the Facility of the Year ... key areas: Outstanding quality of care / satisfaction, census ... Baldwin was invited to attend the awards banquet held ... am delighted to receive this award on behalf of ...
(Date:2/27/2015)... Fairfax, VA (PRWEB) February 27, 2015 ... currently accepting applications for its next class of Fellows ... the field of radiology business management. , Since ... the significant contributions made by RBMA members to the ... is a prestigious recognition because each Fellow candidate must ...
(Date:2/27/2015)... TX (PRWEB) February 27, 2015 ... H1 2015? provides comprehensive information on the therapeutic ... is a problem in which a woman's hormones ... a common problem among teenage girls and young ... unknown. The report strengthens R&D pipelines by identifying ...
(Date:2/27/2015)... 2015 Prescription Drug “Take-Back” events ... Enforcement Agency (DEA). Today, local law ... utilize the “Take-Back” guidelines for the proper disposal ... Eufaula Prescription Drug Disposal Event , The McInstosh ... Eufaula, Oklahoma as the “Take-Back” site for the ...
(Date:2/27/2015)... ResearchMoz has announced the addition of ... the cell culture protein surface coating market across ... scenario and development prospects of the global cell ... of 2015 to 2019. , Read Complete Report ... research report, titled Global Cell Culture Protein Surface ...
Breaking Medicine News(10 mins):Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 2Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 3Health News:RBMA Issues Call for Fellowship Applicants 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 3Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 4Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 3Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 2Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 3
... Oct. 6 Raymond F. Gist, D.D.S., who practices general ... the American Dental Association (ADA) during a meeting of ... Dr. Gist will assume the ADA presidency in October 2010 ... advocate for oral health. Dr. Gist will be the ...
... Oct. 6 Pre-registered and certified providers in the southwest, ... receive the first doses of the live attenuated pandemic H1N1 ... Pennsylvania Department of Health said today. , This vaccine, ... healthy persons between the ages of 2-49 years of age. ...
... protect people from the H1N1 virus, experts say , TUESDAY, ... offer partial protection against the pandemic H1N1 swine flu, but ... flu, Mexican researchers say. , In a study of hospital ... the researchers found that those who had had a seasonal ...
... , NEW YORK, Oct. 6 Metabolife, a leading brand ... -- a campaign encouraging participants to bring about positive, incremental ... simple, everyday thoughtful actions. The campaign kicked-off with the launch ... it is often the accumulation of small changes that delivers ...
... Individuals, Health Departments Across the State Honored ... public health professionals today were honored with GlaxoSmithKline Child ... programs. All nominees were recognized and winners announced at ... Public Health Association,s annual meeting. , The awards showcase ...
... Fla., Oct. 6 Quepasa Corporation (Pink Sheets: QPSA), one ... new initiatives with famed Beverly Hills plastic surgeon Dr. Robert ... an accomplished surgeon, medical consultant and author, best known as ... the E! Network. , Under an existing partnership, whereby ...
Cached Medicine News:Health News:Michigan Dentist Chosen President-Elect of the American Dental Association 2Health News:Health Department Announces First Doses of H1N1 Vaccine Arrive in Pennsylvania 2Health News:Seasonal Flu Vaccine May Lessen Swine Flu Impact 2Health News:Communities Nationwide Learn 'Less Is More' from Metabolife(R) Through 1,000 In-Home Parties and An Interactive Site www.joinlessismore.com 2Health News:Communities Nationwide Learn 'Less Is More' from Metabolife(R) Through 1,000 In-Home Parties and An Interactive Site www.joinlessismore.com 3Health News:GlaxoSmithKline Applauds Compassion, Competence, Passion and Perseverance in North Carolina's Child Advocates 2Health News:GlaxoSmithKline Applauds Compassion, Competence, Passion and Perseverance in North Carolina's Child Advocates 3Health News:GlaxoSmithKline Applauds Compassion, Competence, Passion and Perseverance in North Carolina's Child Advocates 4Health News:GlaxoSmithKline Applauds Compassion, Competence, Passion and Perseverance in North Carolina's Child Advocates 5Health News:GlaxoSmithKline Applauds Compassion, Competence, Passion and Perseverance in North Carolina's Child Advocates 6Health News:Quepasa to Launch New Micro Blog and Mobile Initiatives With Dr. Rey 2
(Date:2/26/2015)... 2015  Mobility Ventures LLC, an AM General Company, ... America (NYSE: BAC ) that will make ... the revolutionary MV-1 - - the world,s first and ... to provide safe and comfortable transportation for all passengers ... to purchase a new MV-1 vehicle at the over ...
(Date:2/26/2015)... Feb. 26, 2015 Legislation passed today by ... provision to help prevent inappropriate prescriptions in Medicare Part ... the Integrity of Medicare Act (PIMA) of 2014 , ... Kevin Brady (R-TX) and Ranking Member Jim McDermott ... abuse epidemic and implement the right policies, said the ...
(Date:2/26/2015)... 2015 LifeScienceIndustryResearch.com adds Global ... Class Innovations and Cost Optimization Plays Major Role ... Companies research report to the pharmaceuticals intelligence collection ... Global Pharma US & EU Outlook 2015 report, ... of non-core assets result in healthy cash position ...
Breaking Medicine Technology:Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4
... 14, 2011 WaferGen Biosystems, Inc. (OTC Bulletin Board: ... systems, today reported financial results for the three months and ... revenue growth in 2010 to a total of $2.2 million ... $1.5 to $2 million for the year," said Alnoor Shivji, ...
... Inc. (Nasdaq: BNVI ) announced today that it will ... ended December 31, 2010 on Tuesday, March 15, 2011. The Company ... results on Tuesday, March 15, 2011, at 5:30 p.m. ET. ... can listen via a live audio only webcast, which can be ...
Cached Medicine Technology:WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 2WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 3WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 4WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 5WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 6WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 7WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 8
... offers specialized imaging systems for very low ... are available. For the most demanding cases, ... thinned, back-illuminated CCD, high resolution (1 million ... reliable, easy to use, achieves ultra-cold temperatures ...
... The ODEI750D cameras are a new generation ... gap between digital and video imaging. Images are ... output in both video and digital formats. Video ... digital images are sent to the PC as ...
Remote Blower Without Bag-In/Bag-Out Option...
... provides a safe, clean environment for ... accord with USP-797 requirements. HEPA filtration ... cleanliness conditions in the work area. ... tilt-up front panel for easy access ...
Medicine Products: